Hereditary folate malabsorption

Last updated
Hereditary folate malabsorption
Other namesCongenital folate malabsorption
Autosomal recessive - en.svg
Hereditary folate malabsorption is inherited in an autosomal recessive manner
Specialty Medical genetics

Hereditary folate malabsorption (HFM) is a rare autosomal recessive disorder caused by loss-of-function mutations in the proton-coupled folate transporter (PCFT) gene, resulting in systemic folate deficiency and impaired delivery of folate to the brain.

Contents

Signs and symptoms

Affected infants present within a few months after birth with failure to thrive and severe folate deficiency manifested as macrocytic anemia and developmental delays. There can be (i) pancytopenia, (ii) diarrhea and/or mucositis and/or (iii) immune deficiency due to T-cell dysfunction and hypoimmunoglobulinemia resulting in pneumonia usually due to Pneumocystis jirovecii . [1] Recently, several infants with the immune deficiency syndrome were described. [2] [3] [4] Untreated, or with inadequate treatment, there are progressive systemic and neurological signs with a spectrum of manifestations including seizures that are often intractable. Females with HFM are fertile and, if folate sufficient during pregnancy, have normal offspring. Subjects that carry one mutated PCFT allele are normal. The genomic and clinical features of HFM were recently reviewed. [1] [4] [5]

Pathophysiology

Extensive clinical studies established that HFM is due to (i) impaired intestinal absorption of folates and (ii) impaired transport of folates across the blood-choroid plexus-cerebrospinal fluid (CSF) barrier. [1] [6] [7] [8] Hence, patients with HFM have very low or undetectable folate blood levels. When a modest dose of a folate is given by mouth, there is impaired intestinal folate absorption without other signs of malabsorption.[ citation needed ]

Molecular pathogenesis

The molecular basis for HFM was established in 2006 with the identification of the proton-coupled folate transporter (PCFT) as the mechanism of intestinal absorption of folates and the detection of loss-of-function mutations in this transporter in subjects with a clinical diagnosis of HFM. [9] [10] Hence, beyond the characteristic clinical features, genotyping is now available to establish the diagnosis of HFM.[ citation needed ]

PCFT

PCFT is located on chromosome 17q11.2 and consists of 459 amino acids, with five exons, and a MW of approximately 50kDa. [9] The secondary structure has been established and consists of twelve transmembrane domains with the N- and C- termini directed into the cytoplasm. [11] [12] The properties of this transporter and its physiological and pharmacological roles were recently reviewed. [13] [14] Elements of PCFT regulation have been described and include the minimal promoter, [15] [16] Vitamin D [17] and NRF1 [18] response elements. PCFT operates most efficiently when there is a strong transmembrane pH gradient. Under these conditions transport of a folate molecule across the cell membrane is accompanied by a sufficient number of protons to result a positive charge and current mediated by the ternary carrier complex. [9] [19] It is the pH gradient present across the apical brush-border membrane of the proximal jejunum, [20] where PCFT is highly expressed, that drives intestinal folate absorption. [20] [21] PCFT is expressed to a lesser extent elsewhere in the small and large intestine along with the canalicular membrane of the hepatic sinusoid and in the apical brush-border membrane of the proximal tubule of the kidney. However, its function at these latter sites is unclear. [22] As indicated above, PCFT is also expressed at the basolateral membrane of ependymal cells of the choroid plexus where it presumably plays a role in transport of folates into the CSF. [22]

Diagnosis

The CSF folate level is usually undetectable at the time of diagnosis. Even when the blood folate level is corrected, or far above normal, the CSF folate level remains low, consistent with impaired transport across the choroid plexus. The normal CSF folate level in children over the first three years of life is in the 75 to 150 nM range. [23] [24] In subjects with HFM it is rarely possible to bring the CSF folate level into the normal range even with substantial doses of parenteral folate. [25]

Differential diagnosis

HFM must be distinguished from cerebral folate deficiency (CFD)– a syndrome in which there is normal intestinal folate absorption, without systemic folate deficiency, but a decrease in CSF folate levels. This can accompany a variety of disorders. [26] One form of CFD is due to loss-of-mutations in folate receptor-α, (FRα), which transports folates via an endocytic process. [27] [28] [29] While PCFT is expressed primarily at the basolateral membrane of the choroid plexus, FRα is expressed primarily at the apical brush-border membrane. [30] Unlike subjects with HFM, patients with CFD present with neurological signs a few years after birth. The basis for the delay in the appearance of clinical manifestations due to loss of FRα function is not clear; the normal blood folate levels may be protective, although for a limited time.[ citation needed ]

Treatment

Because HFM is a rare disorder, there are no studies that define its optimal treatment. Correction of the systemic folate deficiency, with the normalization of folate blood levels, is easily achieved with high doses of oral folates or much smaller doses of parenteral folate. [1] [6] [7] [8] This will rapidly correct the anemia, immune deficiency and GI signs. The challenge is to achieve adequate treatment of the neurological component of HFM. It is essential that the folate dose is sufficiently high to achieve CSF folate levels as close as possible to the normal range for the age of the child. [23] [24] This requires close monitoring of the CSF folate level. [25] The physiological folate is 5-methyltetrahydrofolate but the oral formulation available is insufficient for treatment of this disorder and a parenteral form is not available. The optimal folate at this time is 5-formyltetrahydrofolate which, after administration, is converted to 5-methyltetrahydrofolate. The racemic mixture of 5-formyltetrahydrofolate (leucovorin) is generally available; the active S-isomer, levoleucovorin, may be obtained as well. Parenteral administration is the optimal treatment if that is possible. Folic acid should not be used for the treatment of HFM. Folic acid is not a physiological folate. It binds tightly to, and may impede, FRα-mediated endocytosis which plays an important role in the transport of folates across the choroid plexus into the CSF (see above). [30] [22] For a further consideration of treatment see GeneReviews. [5]

Epidemiology

As of June 2014 (the latest update on HFM [5] in GeneReviews) a total of 32 families had been reported with a clinical diagnosis of HFM of which there was genotypic confirmation in 24 families. Since then, another two confirmed cases have been reported [3] [4] and an additional case was reported based on a clinical diagnosis alone. [31] Most cases emerge from consanguineous parents with homozygous mutations. There are three instances of HFM from non-consanguineous parents in which there were heterozygous mutations. HFM cases are worldwide with mostly private mutations. However, a number of families of Puerto Rican ancestry have been reported with a common pathogenic variant at a splice receptor site resulting in the deletion of exon 3 and the absence of transport function. [2] [5] [9] [32] A subsequent population-based study of newborn infants in Puerto Rico identified the presence of the same variant on the island. [33] Most of the pathogenic variants result in a complete loss of the PCFT protein or point mutations that result in the complete loss of function. However, residual function can be detected with some of the point mutants. [34]

Figures

May Grunwald-Giemsa staining of bone marrow cells taken from a patient with hereditary folate malabsorption, from a case report by Yukari Sakurai et al., 2022 Hyperplasia of erythrocyte series was confirmed and the red arrows were showing megaloblastic change; the ratio of myeloid cells to erythroid cells was found to be markedly decreased to 0.36. The nucleated cell count was 105 x 109/L. The number of megakaryocytes was reduced (0.016 x 109/L) for hyperplastic bone marrow. Bone marrow smear with May Grunwald-Giemsa staining.png
May Grünwald–Giemsa staining of bone marrow cells taken from a patient with hereditary folate malabsorption, from a case report by Yukari Sakurai et al., 2022 Hyperplasia of erythrocyte series was confirmed and the red arrows were showing megaloblastic change; the ratio of myeloid cells to erythroid cells was found to be markedly decreased to 0.36. The nucleated cell count was 105 × 109/L. The number of megakaryocytes was reduced (0.016 × 109/L) for hyperplastic bone marrow.

See also

Related Research Articles

<span class="mw-page-title-main">Intrinsic factor</span> Glycoprotein produced in the stomach which binds to vitamin B12

Intrinsic factor (IF), cobalamin binding intrinsic factor, also known as gastric intrinsic factor (GIF), is a glycoprotein produced by the parietal cells (in humans) or chief cells (in rodents) of the stomach. It is necessary for the absorption of vitamin B12 later on in the distal ileum of the small intestine. In humans, the gastric intrinsic factor protein is encoded by the CBLIF gene. Haptocorrin (transcobalamin I) is another glycoprotein secreted by the salivary glands which binds to vitamin B12. Vitamin B12 is acid-sensitive and in binding to haptocorrin it can safely pass through the acidic stomach to the duodenum.

<span class="mw-page-title-main">Choroid plexus</span> Structure in the ventricles of the brain

The choroid plexus, or plica choroidea, is a plexus of cells that arises from the tela choroidea in each of the ventricles of the brain. Regions of the choroid plexus produce and secrete most of the cerebrospinal fluid (CSF) of the central nervous system. The choroid plexus consists of modified ependymal cells surrounding a core of capillaries and loose connective tissue. Multiple cilia on the ependymal cells move to circulate the cerebrospinal fluid.

<span class="mw-page-title-main">Malabsorption</span> Abnormality in absorption of food nutrients across the gastrointestinal tract

Malabsorption is a state arising from abnormality in absorption of food nutrients across the gastrointestinal (GI) tract. Impairment can be of single or multiple nutrients depending on the abnormality. This may lead to malnutrition and a variety of anaemias.

<span class="mw-page-title-main">Antiporter</span> Class of transmembrane transporter protein

An antiporter is an integral membrane protein that uses secondary active transport to move two or more molecules in opposite directions across a phospholipid membrane. It is a type of cotransporter, which means that uses the energetically favorable movement of one molecule down its electrochemical gradient to power the energetically unfavorable movement of another molecule up its electrochemical gradient. This is in contrast to symporters, which are another type of cotransporter that moves two or more ions in the same direction, and primary active transport, which is directly powered by ATP.

<span class="mw-page-title-main">Folate deficiency</span> Abnormally low level of folate (vitamin B9) in the body

Folate deficiency, also known as vitamin B9 deficiency, is a low level of folate and derivatives in the body. This may result in megaloblastic anemia in which red blood cells become abnormally large, and folate deficiency anemia is the term given for this medical condition. Signs of folate deficiency are often subtle. Symptoms may include fatigue, heart palpitations, shortness of breath, feeling faint, open sores on the tongue, loss of appetite, changes in the color of the skin or hair, irritability, and behavioral changes. Temporary reversible infertility may occur. Folate deficiency anemia during pregnancy may give rise to the birth of low weight birth premature infants and infants with neural tube defects.

<span class="mw-page-title-main">Thiamine transporter 1</span> Mammalian protein found in Homo sapiens

Thiamine transporter 1, also known as thiamine carrier 1 (TC1) or solute carrier family 19 member 2 (SLC19A2) is a protein that in humans is encoded by the SLC19A2 gene. SLC19A2 is a thiamine transporter. Mutations in this gene cause thiamine-responsive megaloblastic anemia syndrome (TRMA), which is an autosomal recessive disorder characterized by diabetes mellitus, megaloblastic anemia and sensorineural deafness.

<span class="mw-page-title-main">Thiamine transporter 2</span> Protein-coding gene in the species Homo sapiens

Thiamine transporter 2 (ThTr-2), also known as solute carrier family 19 member 3, is a protein that in humans is encoded by the SLC19A3 gene. SLC19A3 is a thiamine transporter.

<span class="mw-page-title-main">Sodium/glucose cotransporter 1</span>

Sodium/glucose cotransporter 1 (SGLT1) also known as solute carrier family 5 member 1 is a protein in humans that is encoded by the SLC5A1 gene which encodes the production of the SGLT1 protein to line the absorptive cells in the small intestine and the epithelial cells of the kidney tubules of the nephron for the purpose of glucose uptake into cells. Recently, it has been seen to have functions that can be considered as promising therapeutic target to treat diabetes and obesity. Through the use of the sodium glucose cotransporter 1 protein, cells are able to obtain glucose which is further utilized to make and store energy for the cell.

<span class="mw-page-title-main">Major facilitator superfamily</span>

The major facilitator superfamily (MFS) is a superfamily of membrane transport proteins that facilitate movement of small solutes across cell membranes in response to chemiosmotic gradients.

<span class="mw-page-title-main">Proton-coupled amino acid transporter 1</span> Protein-coding gene in the species Homo sapiens

Proton-coupled amino acid transporter 1 is a protein that in humans is encoded by the SLC36A1 gene.

<span class="mw-page-title-main">Choroid plexus carcinoma</span> Medical condition

A choroid plexus carcinoma is a type of choroid plexus tumor that affects the choroid plexus of the brain. It is considered the worst of the three grades of chord plexus tumors, having a much poorer prognosis than choroid atypical plexus papilloma and choroid plexus papilloma. The disease creates lesions in the brain and increases cerebrospinal fluid volume, resulting in hydrocephalus.

<span class="mw-page-title-main">Iminoglycinuria</span> Medical condition

Iminoglycinuria is an autosomal recessive disorder of renal tubular transport affecting reabsorption of the amino acid glycine, and the imino acids proline and hydroxyproline. This results in excess urinary excretion of all three acids.

<span class="mw-page-title-main">Imerslund–Gräsbeck syndrome</span> Medical condition

Imerslund–Gräsbeck syndrome is a rare autosomal recessive, familial form of vitamin B12 deficiency caused by malfunction of the "Cubam" receptor located in the terminal ileum. This receptor is composed of two proteins, amnionless (AMN), and cubilin. A defect in either of these protein components can cause this syndrome. This is a rare disease, with a prevalence about 1 in 200,000, and is usually seen in patients of European ancestry.

Bile acid malabsorption (BAM), known also as bile acid diarrhea, is a cause of several gut-related problems, the main one being chronic diarrhea. It has also been called bile acid-induced diarrhea, cholerheic or choleretic enteropathy, bile salt diarrhea or bile salt malabsorption. It can result from malabsorption secondary to gastrointestinal disease, or be a primary disorder, associated with excessive bile acid production. Treatment with bile acid sequestrants is often effective. Depending on the severity of symptoms, it may be recognised as a disability in the United Kingdom under the Equality Act 2010.

Haem or Heme carrier protein 1 (HCP1) was originally identified as mediating heme-Fe transport although it later emerged that it was the SLC46A1 folate transporter.

<span class="mw-page-title-main">Proton-coupled folate transporter</span> Mammalian protein found in Homo sapiens

The proton-coupled folate transporter is a protein that in humans is encoded by the SLC46A1 gene. The major physiological roles of PCFTs are in mediating the intestinal absorption of folate, and its delivery to the central nervous system.

<span class="mw-page-title-main">Natural resistance-associated macrophage protein</span> Family of transport proteins

Natural resistance-associated macrophage proteins (Nramps), also known as metal ion (Mn2+-iron) transporters (TC# 2.A.55), are a family of metal transport proteins found throughout all domains of life. Taking on an eleven-helix LeuT fold, the Nramp family is a member of the large APC Superfamily of secondary carriers. They transport a variety of transition metals such as manganese, cadmium, and manganese using an alternating access mechanism characteristic of secondary transporters.

<span class="mw-page-title-main">Cerebral folate deficiency</span> Medical condition

Cerebral folate deficiency is a condition in which concentrations of 5-methyltetrahydrofolate are low in the brain as measured in the cerebral spinal fluid despite being normal in the blood. Symptoms typically appear at about 5 to 24 months of age. Without treatment there may be poor muscle tone, trouble with coordination, trouble talking, and seizures.

Proton-coupled amino acid transporters belong to the SLC26A5 family; they are protein receptors whose main function is the transmembrane movement of amino acids and their derivatives. This family of receptors is most commonly found within the luminal surface of the small intestine as well as in some lysosomes. The solute carrier family (SLC) of genes includes roughly 400 membrane proteins that are characterized by 66 families in total. The SLC36 family of genes maps to chromosome 11. The diversity of these receptors is vast, with the ability to transport both charged and uncharged amino acids along with their derivatives. In research and practice, SLC36A1/2 are both targets for drug-based delivery systems for a wide range of disorders.

The mitochondrial folate transporter (MTF) is a transport protein that facilitates the transfer of tetrahydrofolate across the inner mitochondrial membrane. It is encoded by the SLC25A32 gene and belongs to the mitochondrial carrier superfamily.

References

  1. 1 2 3 4 Geller, J; Kronn, D; Jayabose, S; Sandoval, C (January 2002). "Hereditary folate malabsorption: family report and review of the literature". Medicine. 81 (1): 51–68. doi: 10.1097/00005792-200201000-00004 . PMID   11807405. S2CID   27156694.
  2. 1 2 Borzutzky, A; Crompton, B; Bergmann, AK; Giliani, S; Baxi, S; Martin, M; Neufeld, EJ; Notarangelo, LD (December 2009). "Reversible severe combined immunodeficiency phenotype secondary to a mutation of the proton-coupled folate transporter". Clinical Immunology (Orlando, Fla.). 133 (3): 287–94. doi:10.1016/j.clim.2009.08.006. PMC   2783538 . PMID   19740703.
  3. 1 2 Kishimoto, K; Kobayashi, R; Sano, H; Suzuki, D; Maruoka, H; Yasuda, K; Chida, N; Yamada, M; Kobayashi, K (July 2014). "Impact of folate therapy on combined immunodeficiency secondary to hereditary folate malabsorption". Clinical Immunology (Orlando, Fla.). 153 (1): 17–22. doi:10.1016/j.clim.2014.03.014. PMID   24691418.
  4. 1 2 3 Erlacher, M; Grünert, SC; Cseh, A; Steinfeld, R; Salzer, U; Lausch, E; Nosswitz, U; Dückers, G; Niehues, T; Ehl, S; Niemeyer, CM; Speckmann, C (June 2015). "Reversible pancytopenia and immunodeficiency in a patient with hereditary folate malabsorption". Pediatric Blood & Cancer. 62 (6): 1091–4. doi: 10.1002/pbc.25364 . PMID   25504888. S2CID   35727871.
  5. 1 2 3 4 Diop-Bove, N; Kronn, D; Goldman, ID; Pagon, RA; Adam, MP; Ardinger, HH; Wallace, SE; Amemiya, A; Bean, LJH; Bird, TD; Dolan, CR; Fong, CT; Smith, RJH; Stephens, K (1993). "Hereditary Folate Malabsorption". PMID   20301716.{{cite journal}}: Cite journal requires |journal= (help)
  6. 1 2 Lanzkowsky, P; Erlandson, ME; Bezan, AI (October 1969). "Isolated defect of folic acid absorption associated with mental retardation and cerebral calcification". Blood. 34 (4): 452–65. doi: 10.1182/blood.V34.4.452.452 . PMID   4980683.
  7. 1 2 Poncz, M; Colman, N; Herbert, V; Schwartz, E; Cohen, AR (January 1981). "Therapy of congenital folate malabsorption". The Journal of Pediatrics. 98 (1): 76–9. doi:10.1016/s0022-3476(81)80541-0. PMID   6969796.
  8. 1 2 Urbach, J; Abrahamov, A; Grossowicz, N (January 1987). "Congenital isolated folic acid malabsorption". Archives of Disease in Childhood. 62 (1): 78–80. doi:10.1136/adc.62.1.78. PMC   1778153 . PMID   3813642.
  9. 1 2 3 4 Qiu, A; Jansen, M; Sakaris, A; Min, SH; Chattopadhyay, S; Tsai, E; Sandoval, C; Zhao, R; Akabas, MH; Goldman, ID (1 December 2006). "Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption". Cell. 127 (5): 917–28. doi: 10.1016/j.cell.2006.09.041 . PMID   17129779.
  10. ↑ Zhao, R; Min, SH; Qiu, A; Sakaris, A; Goldberg, GL; Sandoval, C; Malatack, JJ; Rosenblatt, DS; Goldman, ID (15 August 2007). "The spectrum of mutations in the PCFT gene, coding for an intestinal folate transporter, that are the basis for hereditary folate malabsorption". Blood. 110 (4): 1147–52. doi:10.1182/blood-2007-02-077099. PMC   1939898 . PMID   17446347.
  11. ↑ Duddempudi, PK; Goyal, R; Date, SS; Jansen, M (2013). "Delineating the extracellular water-accessible surface of the proton-coupled folate transporter". PLOS ONE. 8 (10): e78301. Bibcode:2013PLoSO...878301D. doi: 10.1371/journal.pone.0078301 . PMC   3799626 . PMID   24205192.
  12. ↑ Zhao, R; Unal, ES; Shin, DS; Goldman, ID (6 April 2010). "Membrane topological analysis of the proton-coupled folate transporter (PCFT-SLC46A1) by the substituted cysteine accessibility method". Biochemistry. 49 (13): 2925–31. doi:10.1021/bi9021439. PMC   2866095 . PMID   20225891.
  13. ↑ Zhao, R; Goldman, ID (2013). "Folate and thiamine transporters mediated by facilitative carriers (SLC19A1-3 and SLC46A1) and folate receptors". Molecular Aspects of Medicine. 34 (2–3): 373–85. doi:10.1016/j.mam.2012.07.006. PMC   3831518 . PMID   23506878.
  14. ↑ Desmoulin, SK; Hou, Z; Gangjee, A; Matherly, LH (December 2012). "The human proton-coupled folate transporter: Biology and therapeutic applications to cancer". Cancer Biology & Therapy. 13 (14): 1355–73. doi:10.4161/cbt.22020. PMC   3542225 . PMID   22954694.
  15. ↑ Stark, M; Gonen, N; Assaraf, YG (9 October 2009). "Functional elements in the minimal promoter of the human proton-coupled folate transporter". Biochemical and Biophysical Research Communications. 388 (1): 79–85. doi:10.1016/j.bbrc.2009.07.116. PMID   19643086.
  16. ↑ Diop-Bove, NK; Wu, J; Zhao, R; Locker, J; Goldman, ID (August 2009). "Hypermethylation of the human proton-coupled folate transporter (SLC46A1) minimal transcriptional regulatory region in an antifolate-resistant HeLa cell line". Molecular Cancer Therapeutics. 8 (8): 2424–31. doi:10.1158/1535-7163.mct-08-0938. PMC   2735101 . PMID   19671745.
  17. ↑ Eloranta, JJ; Zaïr, ZM; Hiller, C; Häusler, S; Stieger, B; Kullak-Ublick, GA (November 2009). "Vitamin D3 and its nuclear receptor increase the expression and activity of the human proton-coupled folate transporter". Molecular Pharmacology. 76 (5): 1062–71. doi:10.1124/mol.109.055392. PMID   19666701. S2CID   11155598.
  18. ↑ Gonen, N; Assaraf, YG (29 October 2010). "The obligatory intestinal folate transporter PCFT (SLC46A1) is regulated by nuclear respiratory factor 1". The Journal of Biological Chemistry. 285 (44): 33602–13. doi: 10.1074/jbc.m110.135640 . PMC   2962458 . PMID   20724482.
  19. ↑ Umapathy, NS; Gnana-Prakasam, JP; Martin, PM; Mysona, B; Dun, Y; Smith, SB; Ganapathy, V; Prasad, PD (November 2007). "Cloning and functional characterization of the proton-coupled electrogenic folate transporter and analysis of its expression in retinal cell types". Investigative Ophthalmology & Visual Science. 48 (11): 5299–305. doi:10.1167/iovs.07-0288. PMC   3850295 . PMID   17962486.
  20. 1 2 Said, HM; Smith, R; Redha, R (November 1987). "Studies on the intestinal surface acid microclimate: developmental aspects". Pediatric Research. 22 (5): 497–9. doi: 10.1203/00006450-198711000-00002 . PMID   3684377.
  21. ↑ Visentin, M; Diop-Bove, N; Zhao, R; Goldman, ID (2014). "The intestinal absorption of folates". Annual Review of Physiology. 76: 251–74. doi:10.1146/annurev-physiol-020911-153251. PMC   3982215 . PMID   24512081.
  22. 1 2 3 Zhao, R; Diop-Bove, N; Visentin, M; Goldman, ID (21 August 2011). "Mechanisms of membrane transport of folates into cells and across epithelia". Annual Review of Nutrition. 31: 177–201. doi:10.1146/annurev-nutr-072610-145133. PMC   3885234 . PMID   21568705.
  23. 1 2 Ormazabal, A; García-Cazorla, A; Pérez-Dueñas, B; Gonzalez, V; Fernández-Alvarez, E; Pineda, M; Campistol, J; Artuch, R (September 2006). "Determination of 5-methyltetrahydrofolate in cerebrospinal fluid of paediatric patients: reference values for a paediatric population". Clinica Chimica Acta. 371 (1–2): 159–62. doi:10.1016/j.cca.2006.03.004. PMID   16624264.
  24. 1 2 Verbeek, MM; Blom, AM; Wevers, RA; Lagerwerf, AJ; van de Geer, J; Willemsen, MA (November 2008). "Technical and biochemical factors affecting cerebrospinal fluid 5-MTHF, biopterin and neopterin concentrations". Molecular Genetics and Metabolism. 95 (3): 127–32. doi:10.1016/j.ymgme.2008.07.004. PMID   18722797.
  25. 1 2 Torres, A; Newton, SA; Crompton, B; Borzutzky, A; Neufeld, EJ; Notarangelo, L; Berry, GT (26 May 2015). CSF 5-Methyltetrahydrofolate Serial Monitoring to Guide Treatment of Congenital Folate Malabsorption Due to Proton-Coupled Folate Transporter (PCFT) Deficiency. Vol. 24. pp. 91–6. doi:10.1007/8904_2015_445. ISBN   978-3-662-48226-1. PMC   4582027 . PMID   26006721.{{cite book}}: |work= ignored (help)
  26. ↑ Hyland, K; Shoffner, J; Heales, SJ (October 2010). "Cerebral folate deficiency". Journal of Inherited Metabolic Disease. 33 (5): 563–70. doi:10.1007/s10545-010-9159-6. PMID   20668945. S2CID   25555372.
  27. ↑ Steinfeld, R; Grapp, M; Kraetzner, R; Dreha-Kulaczewski, S; Helms, G; Dechent, P; Wevers, R; Grosso, S; Gärtner, J (September 2009). "Folate receptor alpha defect causes cerebral folate transport deficiency: a treatable neurodegenerative disorder associated with disturbed myelin metabolism". American Journal of Human Genetics. 85 (3): 354–63. doi:10.1016/j.ajhg.2009.08.005. PMC   2771535 . PMID   19732866.
  28. ↑ Grapp, M; Just, IA; Linnankivi, T; Wolf, P; Lücke, T; Häusler, M; Gärtner, J; Steinfeld, R (July 2012). "Molecular characterization of folate receptor 1 mutations delineates cerebral folate transport deficiency". Brain: A Journal of Neurology. 135 (Pt 7): 2022–31. doi: 10.1093/brain/aws122 . PMID   22586289.
  29. ↑ Toelle, SP; Wille, D; Schmitt, B; Scheer, I; Thöny, B; Plecko, B (March 2014). "Sensory stimulus-sensitive drop attacks and basal ganglia calcification: new findings in a patient with FOLR1 deficiency". Epileptic Disorders. 16 (1): 88–92. doi:10.1684/epd.2014.0629. PMID   24556562.
  30. 1 2 Grapp, M; Wrede, A; Schweizer, M; Hüwel, S; Galla, HJ; Snaidero, N; Simons, M; Bückers, J; Low, PS; Urlaub, H; Gärtner, J; Steinfeld, R (2013). "Choroid plexus transcytosis and exosome shuttling deliver folate into brain parenchyma". Nature Communications. 4: 2123. Bibcode:2013NatCo...4.2123G. doi: 10.1038/ncomms3123 . hdl: 11858/00-001M-0000-0014-164F-1 . PMID   23828504.
  31. ↑ Ahmad, I; Mukhtar, G; Iqbal, J; Ali, SW (January 2015). "Hereditary folate malabsorption with extensive intracranial calcification". Indian Pediatrics. 52 (1): 67–8. doi:10.1007/s13312-015-0571-8. PMID   25638192. S2CID   40024396.
  32. ↑ Santiago-Borrero, PJ; Santini R, Jr; Pérez-Santiago, E; Maldonado, N (March 1973). "Congenital isolated defect of folic acid absorption". The Journal of Pediatrics. 82 (3): 450–5. doi:10.1016/s0022-3476(73)80119-2. PMID   4540608.
  33. ↑ Mahadeo, KM; Diop-Bove, N; Ramirez, SI; Cadilla, CL; Rivera, E; Martin, M; Lerner, NB; DiAntonio, L; Duva, S; Santiago-Borrero, PJ; Goldman, ID (October 2011). "Prevalence of a loss-of-function mutation in the proton-coupled folate transporter gene (PCFT-SLC46A1) causing hereditary folate malabsorption in Puerto Rico". The Journal of Pediatrics. 159 (4): 623–7.e1. doi:10.1016/j.jpeds.2011.03.005. PMC   3935241 . PMID   21489556.
  34. ↑ Mahadeo, K; Diop-Bove, N; Shin, D; Unal, ES; Teo, J; Zhao, R; Chang, MH; Fulterer, A; Romero, MF; Goldman, ID (November 2010). "Properties of the Arg376 residue of the proton-coupled folate transporter (PCFT-SLC46A1) and a glutamine mutant causing hereditary folate malabsorption". American Journal of Physiology. Cell Physiology. 299 (5): C1153–61. doi:10.1152/ajpcell.00113.2010. PMC   2980313 . PMID   20686069.
  35. ↑ Sakurai, Y., Toriumi, N., Sarashina, T. et al. An infantile case of hereditary folate malabsorption with sudden development of pulmonary hemorrhage: a case report. J Med Case Reports 16, 268 (2022). https://doi.org/10.1186/s13256-022-03448-x
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.